Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

Inclusion Criteria cohorts 1-4: 1. Provided evidence of a signed consent 2. Age ≥ 18 and ≤ 75 years 3. Healthy overweight/obese adult men and women with body mass index ≥ 27 and ≤ 40 kg/m2 4. No nicotine use 5. Have a suitable venous access for blood sampling Inclusion Criteria cohort 5: 1. Men and women with T2DM of ≥6 months duration 2. Age ≥ 18 and ≤ 75 years 3. BMI ≥ 27 and ≤ 40 kg/m2 4. Treated with stable doses of ≥500 mg of metformin with a duration ≥6 months and at stable doses for ≥2 months with a screening HbA1c ≥7.0% and ≤10.5%. Exclusion Criteria: 1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within the major 3 months 2. A sitting BP after resting for 5 minutes \> 160mm Hg systolic or \> 100 mm Hg diastolic or an apical pulse rate \<50 or \>100 beats per minute. 3. Evidence of abnormality on the screening visit ECG, or a history of known arrhythmia or prolonged QTcF pr prolonged QRS interval 4. Liver function test results elevated \> 2.0-fold above the ULN for gamma glutamyl transferase, alkaline phosphatase, aspartate aminotransferase or alanine aminotransferase. Bilirubin above the ULN 5. Estimated glomerular filtration rate \< 60mL/min/1.73 m2 body surface area 6. Known hypersensitivity to any of the study drug ingredients 7. Any other condition or prior therapy that would make the participant unsuitable for this study